Overview

Study to Assess the Safety and Tolerability of REGN5837 in Combination With Odronextamab in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Status:
Not yet recruiting
Trial end date:
2029-04-16
Target enrollment:
Participant gender:
Summary
The primary objective of the study is: To assess the safety, tolerability, and dose-limiting toxicities (DLTs) and to determine recommended phase 2 dose (RP2D) regimen(s) (defined as either a maximum tolerated dose (MTD) regimen or a lower dose regimen) of REGN5837 in combination with odronextamab in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL) The secondary objectives of the study are: - To evaluate the pharmacokinetics (PK) of REGN5837 when given in combination with odronextamab - To evaluate the PK of odronextamab when given in combination with REGN5837 - To assess the immunogenicity of REGN5837 and odronextamab - To assess the preliminary anti-tumor activity of REGN5837 in combination with odronextamab in patients with relapsed or refractory aggressive B-NHL
Phase:
Phase 1
Details
Lead Sponsor:
Regeneron Pharmaceuticals